Search

Your search keyword '"Marrosu, M. G."' showing total 21 results
Start Over Author "Marrosu, M. G." Journal neurology
21 results on '"Marrosu, M. G."'

1. Familial effects on the clinical course of multiple sclerosis

Author

Hensiek, A. E., primary, Seaman, S. R., additional, Barcellos, L. F., additional, Oturai, A., additional, Eraksoi, M., additional, Cocco, E., additional, Vecsei, L., additional, Stewart, G., additional, Dubois, B., additional, Bellman-Strobl, J., additional, Leone, M., additional, Andersen, O., additional, Bencsik, K., additional, Booth, D., additional, Celius, E. G., additional, Harbo, H. F., additional, Hauser, S. L., additional, Heard, R., additional, Hillert, J., additional, Myhr, K. -M., additional, Marrosu, M. G., additional, Oksenberg, J. R., additional, Rajda, C., additional, Sawcer, S. J., additional, Sorensen, P. S., additional, Zipp, F., additional, and Compston, D.A.S., additional

Published
2007
Full Text
View/download PDF

4. Multiple Sclerosis Severity Score: Using disability and disease duration to rate disease severity

Author

Roxburgh, R. H.S.R., primary, Seaman, S. R., additional, Masterman, T., additional, Hensiek, A. E., additional, Sawcer, S. J., additional, Vukusic, S., additional, Achiti, I., additional, Confavreux, C., additional, Coustans, M., additional, le Page, E., additional, Edan, G., additional, McDonnell, G. V., additional, Hawkins, S., additional, Trojano, M., additional, Liguori, M., additional, Cocco, E., additional, Marrosu, M. G., additional, Tesser, F., additional, Leone, M. A., additional, Weber, A., additional, Zipp, F., additional, Miterski, B., additional, Epplen, J. T., additional, Oturai, A., additional, Sorensen, P. S., additional, Celius, E. G., additional, Lara, N. T., additional, Montalban, X., additional, Villoslada, P., additional, Silva, A. M., additional, Marta, M., additional, Leite, I., additional, Dubois, B., additional, Rubio, J., additional, Butzkueven, H., additional, Kilpatrick, T., additional, Mycko, M. P., additional, Selmaj, K. W., additional, Rio, M. E., additional, Sa, M., additional, Salemi, G., additional, Savettieri, G., additional, Hillert, J., additional, and Compston, D. A.S., additional

Published
2005
Full Text
View/download PDF

8. Autologous hematopoietic stem cell transplantation suppresses Gd-enhanced MRI activity in MS

Author

Mancardi, G. L., primary, Saccardi, R., additional, Filippi, M., additional, Gualandi, F., additional, Murialdo, A., additional, Inglese, M., additional, Marrosu, M. G., additional, Meucci, G., additional, Massacesi, L., additional, Lugaresi, A., additional, Pagliai, F., additional, Sormani, M. P., additional, Sardanelli, F., additional, and Marmont, A., additional

Published
2001
Full Text
View/download PDF

10. Charcot-Marie-Tooth disease type 2 and P0 gene mutations

Author

Pareyson, D., primary, Sghirlanzoni, A., additional, Bolti, S., additional, Ciano, C., additional, Fallica, E., additional, Mora, M., additional, Taroni, F., additional, Marrosu, M. G., additional, Vaccargiu, S., additional, Marrosu, G., additional, Vannelli, A., additional, Cianchetti, C., additional, and Muntoni, F., additional

Published
1999
Full Text
View/download PDF

13. HLA and MS

Author

Haegert, D. G., primary, Muntoni, F., additional, Murru, M. R., additional, Marrosu, M. G., additional, and Francis, G. S., additional

Published
1993
Full Text
View/download PDF

15. HLA‐DQB1 genotype in Sardinian multiple sclerosis

Author

Marrosu, M. G., primary, Muntoni, F., additional, Murru, M. R., additional, Costa, G., additional, Pischedda, M. P., additional, Pirastu, M., additional, Sotgiu, S., additional, Rosati, G., additional, and Cianchetti, C., additional

Published
1992
Full Text
View/download PDF

20. Pregnancy and fetal outcomes after interferon-β exposure in multiple sclerosis.

Author

Amato MP, Portaccio E, Ghezzi A, Hakiki B, Zipoli V, Martinelli V, Moiola L, Patti F, La Mantia L, Mancardi GL, Solaro C, Tola MR, Pozzilli C, De Giglio L, Totaro R, Lugaresi A, Di Tommaso V, Paolicelli D, Marrosu MG, Comi G, Pellegrini F, and Trojano M

Subjects
Abortion, Spontaneous etiology, Abortion, Spontaneous physiopathology, Adult, Cohort Studies, Female, Fetal Diseases chemically induced, Fetal Diseases diagnosis, Fetal Diseases physiopathology, Fetal Weight drug effects, Follow-Up Studies, Humans, Infant, Newborn, Interferon-beta adverse effects, Male, Multiple Sclerosis complications, Pregnancy, Pregnancy Outcome epidemiology, Prospective Studies, Abortion, Spontaneous chemically induced, Interferon-beta therapeutic use, Multiple Sclerosis drug therapy
Abstract

Objective: To assess pregnancy and fetal outcomes after in utero exposure to interferon-β (IFNβ) in all pregnancies occurring in women with multiple sclerosis (MS) during the study period, with a specific focus on the risk of spontaneous abortion., Methods: In this cohort study, data were gathered through a standardized, semi-structured interview. Patients who discontinued IFNβ less than 4 weeks from conception (exposed) were compared with those who had discontinued the drug at least 4 weeks from conception or who were never treated (not exposed). Possible confounders were handled through multivariate analyses adjusted for propensity score (PS)., Results: We collected data on 396 pregnancies in 388 women, 88 classified as exposed (mean exposure 4.6 ± 5.8 weeks). IFNβ exposure was not associated with an increased risk of spontaneous abortion (PS-adjusted odds ratio [OR] 1.08, 95% confidence interval [CI] 0.4 to 2.9, p = 0.88), although it was associated with both lower baby weight (PS-adjusted β -113.8, p < 0.0001) and length (PS-adjusted β -1.102, p < 0.0001). Proportion of spontaneous abortion in exposed patients fell within the range expected for the Italian population in the same period. IFNβ exposure (PS-adjusted OR 2.11, 95% CI 1.18 to 3.78, p = 0.012) and cesarean delivery were the only predictors of preterm delivery. In the exposed group, we did not observe any significant fetal complications, malformations, or developmental abnormalities over a median follow-up of 2.1 years., Conclusions: Our findings point to the relative safety of IFNβ exposure times of up to 4 weeks and can assist neurologists facing therapeutic decisions in women with MS with a pregnancy plan.

Published
2010
Full Text
View/download PDF

21. Anticipation of age at onset in multiple sclerosis: a Sardinian cohort study.

Author

Cocco E, Sardu C, Lai M, Spinicci G, Contu P, and Marrosu MG

Subjects
Adolescent, Adult, Age of Onset, Child, Cohort Studies, Environment, Female, Humans, Italy epidemiology, Life Tables, Male, Middle Aged, Multiple Sclerosis genetics, Public Health trends, Social Change, Survival Analysis, Anticipation, Genetic, Multiple Sclerosis epidemiology
Abstract

Background: To assess the temporal trend in multiple sclerosis (MS) onset during the last 50 years in Sardinia, Italy., Methods: The authors used a cohort study to assess age at onset in 1,513 MS patients at the MS clinic in Cagliari, all born and living in Sardinia. They also assessed age at onset in 41 pairs of familial patients from two generations and 78 pairs of affected sibs. Each familial couple was paired with three couples of sporadic patients born in the same year as the familial ones. The time interval between the first symptoms and diagnosis was analyzed in first and second-diagnosed patients from both familial and control couples., Results: Mean age at onset progressively decreased from the most remote to the most recent decade of birth (log-rank test 778.27, p < 0.0001), being 41 years in the former decade and 22 years in the latter. A genetic influence was ruled out, because the younger member of familial patients coming from two generations had onset 14.0 years earlier than the older one (p < 0.0001), as in the paired control couples (11.6 years, p < 0.0001). Moreover, mean onset in younger sibs was 3.4 years earlier than in older ones (p = 0.01), similar to that of control couples (4.1 years, p < 0.0001)., Conclusion: Age at onset decreases progressively from older to younger generations in Sardinian MS patients. Nongenetic but recent widespread environmental changes might contribute to shortening of the preclinical phase-overt disease interval.

Published
2004
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results